Brief: Phathom Pharmaceuticals Inc submits 6-Month Stability Data In Support Of Erosive Gerd New Drug Application

Phathom Pharmaceuticals

21/08/2023 13:18

Aug 21 (Reuters) - 
  
    * PHATHOM PHARMACEUTICALS INC - SUBMISSION OF SIX-MONTH
STABILITY
DATA IN SUPPORT OF EROSIVE GERD NEW DRUG APPLICATION
    * PHATHOM PHARMA - WITH SUBMISSION OF DATA, CO SATISFIED
FDA'S
REQUEST FOR ADDITIONAL DATA IN RESPONSE TO CRL ISSUED IN FEB
    * PHATHOM PHARMACEUTICALS INC - NDA FOR VONOPRAZAN FOR
EROSIVE
GERD ASSIGNED A PDUFA GOAL DATE OF NOVEMBER 17
    * PHATHOM PHARMA - IF APPROVED, COMBINED U.S. COMMERCIAL
LAUNCH
FOR EROSIVE GERD AND H. PYLORI IS PLANNED FOR Q4

Source text for Eikon:  ID:nGNX7lhgjQ 
Further company coverage:  PHAT.O 

 ((reuters.briefs@thomsonreuters.com))